NCT05422794View on ClinicalTrials.gov

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Triple-Negative Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaUnresectable Triple-Negative Breast Carcinoma
Interventions
DRUG

BET Bromodomain Inhibitor ZEN-3694

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Nab-paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (5)

10016

RECRUITING

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

37204

RECRUITING

Vanderbilt Breast Center at One Hundred Oaks, Nashville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

02118

RECRUITING

Boston Medical Center, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH